ONC201 Featured in Seven Abstracts at 2015 AACR Meeting

• Hummelstown, PA (March 31, 2015) – Oncoceutics, Inc., a drug discovery and development company targeting the most potent suppressor pathways in human cancer, along with its collaborators, has been selected to present at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held in Philadelphia. The seven abstracts selected for presentation include results of preclinical studies that continue to demonstrate the robust efficacy of ONC201, Oncoceutics’ new oncology drug, in aggressive and refractory cancers. The presentations will also further elucidate the mechanism of action that underpins ONC201’s compelling efficacy and safety profile. Clinical trials for ONC201 are currently underway.

  Abstract Details:
  Early integrated stress response induction of ATF4 is required for the anticancer effects of the dual Akt/ERK inhibitor and TRAIL pathway inducer ONC201/TIC10. Kline et al. Abstract Number: 674 Presentation Time: Sunday Apr 19, 2015 1:00 PM – 5:00 PM Session Category: Experimental and Molecular Therapeutics Session Title: Signal Transduction Inhibitors Location: Poster Section 28

  TRAIL pathway inducer ONC201/TIC10 primes multiple myeloma cells (MM) for apoptosis by downregulating X-linked inhibitor of apoptosis. Kline et al. Abstract Number: 2942 Presentation Time: Tuesday Apr 21, 2015 8:00 AM – noon Session Category: Molecular and Cellular Biology Session Title: Cell Death Therapies 1 Location: Poster Section 2

  ONC201/TIC10 targets colorectal cancer stem cells and bulk tumor cells via an Akt-Foxo3a-TRAIL-dependent mechanism. Prabhu et al. Abstract Number: 4241 Presentation Time: Tuesday Apr 21, 2015 1:00 PM – 5:00 PM Session Category: Tumor Biology Session Title: Therapeutics Targeting Cancer Stem Cells Location: Poster Section 21

  In vitro efficacy profiling of ONC201 in cancer cells reveals sensitivity pattern that is consistent with ER stress response. Allen et al. Abstract Number: 4475 Presentation Time: Tuesday Apr 21, 2015 1:00 PM – 5:00 PM Session Category: Experimental and Molecular Therapeutics Session Title: Novel Targets 2 Location: Poster Section 31

  ONC201 is non-toxic at efficacious doses in vitro and in vivo. Allen et al. Abstract Number: 4479 Presentation Time: Tuesday Apr 21, 2015 1:00 PM – 5:00 PM Session Category: Experimental and Molecular Therapeutics Session Title: Novel Targets 2 Location: Poster Section 31

  Cytotoxicity, Biochemical Activity, and Structural Analysis of ONC201 Clinical Material and Comparisons to a Biologically Inactive Isomer. Wagner et al. Abstract Number: 4499 Presentation Time: Tuesday Apr 21, 2015 1:00 PM – 5:00 PM Session Category: Experimental and Molecular Therapeutics Session Title: Novel Targets 2 Location: Poster Section 31

  ONC201/TIC10 is effective as a monoagent and synergizes with chemotherapy to induce cell death in non-Hodgkin’s lymphoma. Talekar et al. Abstract Number: 5387 Presentation Time: Wednesday Apr 22, 2015 8:00 AM – noon Session Category: Experimental and Molecular Therapeutics Session Title: Histone Deacetylase Inhibitors, Methyltransferase Inhibitors, and Other Targets Location: Poster Section 29

  About Oncoceutics
  Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The first lead compound to result from this program is ONC201, a small molecule drug with a unique mechanism of action that causes significant anti-tumor activity in a variety of types of human cancer. The Company is currently enrolling patients in clinical trials of ONC201, which began in January 2015, following acceptance by the U.S. Food and Drug Administration of the Company’s Investigational New Drug (IND) application for ONC201 in 2014. Oncoceutics and collaborative groups have received approximately $5 million in grants over the last two years from the National Institutes of Health, the Pennsylvania Department of Health, and The Musella Foundation, and the company has leveraged additional funding from academic medical research partners that support multiple Phase I/II clinical trials.

  Visit Oncoceutics or contact Rohinton Tarapore for more information.

  Safe Harbor Forward-Looking Statements
  To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Photostream